Over-prescription of short-acting β 2 -agonists is associated with poor asthma outcomes: results from the African cohort of the SABINA III study.
| Autor: | Khattab A; Pulmonary Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Madkour A; Pulmonary Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Ambaram A; Department of Pulmonology, Gateway Centre for Respiratory and Gastrointestinal Disease, Durban, South Africa., Smith C; Morningside Mediclinic, Sandton, Johannesburg, South Africa., Muhwa CJ; Department of Medicine, Therapeutics and Dermatology, Kenyatta University, Nairobi, Kenya.; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom., Mecha JO; Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya., Alsayed M; Medicinal Department, AstraZeneca, Dubai, United Arab Emirates., Beekman MJHI; Respiratory & Immunology, AstraZeneca, The Hague, The Netherlands. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Current medical research and opinion [Curr Med Res Opin] 2022 Nov; Vol. 38 (11), pp. 1983-1995. Date of Electronic Publication: 2022 Aug 27. |
| DOI: | 10.1080/03007995.2022.2100649 |
| Abstrakt: | Background: The extent of short-acting β Methods: Data on disease characteristics/asthma treatments were collected from patients (≥12 years) using electronic case report forms. Patients were classified by investigator-defined asthma severity (guided by the 2017 Global Initiative for Asthma) and practice type (primary/specialist care). Multivariable regression models analyzed associations between SABA prescriptions and outcomes. Results: Data from 1778 patients (mean age, 43.7 years) were analyzed. Most patients were female (62.4%) and had moderate-to-severe asthma (63.3%), with 57.1 and 42.9% of patients treated in specialist and primary care, respectively. Asthma was partly controlled/uncontrolled in 66.2% of patients, with 57.9% experiencing ≥1 severe exacerbation in the previous 12 months. Overall, 46.5% of patients were prescribed ≥3 SABA canisters in the preceding 12 months (over-prescription); 26.2% were prescribed ≥10 canisters. SABAs were purchased over-the-counter by 32.6% of patients, of whom 79.3% had received SABA prescriptions; 71.9% and 40.1% for ≥3 and ≥10 canisters, respectively. Higher SABA prescriptions (vs. 1-2 canisters) were associated with increased incidence rate of severe exacerbations and lower odds of having at least partly controlled asthma (except 3-5 canisters). Conclusions: Findings from this African cohort of the SABINA III study indicate that SABA over-prescription and SABA over-the-counter purchase are common and associated with poor asthma-related outcomes. This highlights the need for healthcare providers/policymakers to align clinical practices with the latest treatment recommendations. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|